Alto Neuroscience

Alto Neuroscience is pleased to announce the close of a $50 million private placement financing, led by Perceptive Advisors, with participation by new and existing institutional investors, including Commodore Capital LP, Vestal Point Capital, and a large biotech-dedicated investor. Alto intends to use the proceeds to accelerate the development of ALTO-207, a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist) and ondansetron, following a successful FDA meeting regarding the development path of the program, as well as for working capital and general corporate purposes.  Read more here: https://lnkd.in/gBhKAp_H   #TRD #financing #biotech #neuroscience #precisionpsychiatry

Alto Neuroscience announced today that it will accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD), following a successful outcome from a recent meeting with the FDA.   The $50 million private placement announced earlier today supports expanded development of ALTO-207, and the Company expects to initiate a Phase 3 study by early 2027 following Phase 3 readiness work and alignment with the FDA on the planned study design.   Read more here: https://lnkd.in/gYJGjEZR #TRD #biotech #neuroscience

We’re excited to share that Dr. Mike Browning presented data from the results from the PAX-D study, as previously published in The Lancet, at the #ECNP Congress 2025 today. The PAX-D results guided Alto Neuroscience’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole. This presentation highlights the potential of ALTO-207, which we believe represents an important step forward in bringing precision psychiatry to those living with depression. #ECNP2025 #AltoNeuroscience #PrecisionPsychiatry #MentalHealthInnovation

Today is World Mental Health Day, dedicated this year to “Access to Services: Mental Health in Catastrophes and Emergencies.” Around the world, millions of people face mental health challenges amplified by crises — from conflict and displacement to natural disasters and global emergencies. Access to timely, compassionate care can be life-changing. At Alto Neuroscience, we believe that improving access starts with innovation: developing more effective, personalized treatments so that everyone, including those affected by catastrophe, can receive care that works for them. This #WorldMentalHealthDay, we stand with communities and frontline responders, committed to advancing science that strengthens resilience and hope. #WorldMentalHealthDay #MentalHealthAwareness #Neuroscience #PrecisionMedicine #AccessToCare #AltoNeuroscience

We are proud to announce that the #FDA has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, or CIAS. ·  ALTO-101 is a novel PDE4 inhibitor that has already shown pro-cognitive effects in healthy volunteers. ·  This designation underscores the significant unmet need for patients living with CIAS, a core feature of schizophrenia that profoundly impacts daily functioning and quality of life. ·  Today, there are no approved treatments for CIAS—and we are determined to change that. At #Alto, we remain committed to advancing precision medicines for neuropsychiatric disorders and bringing hope to millions of patients worldwide. Learn more: https://lnkd.in/gq-uz3xP #Neuroscience #Schizophrenia #CIAS #FastTrack #FDA #BiotechInnovation

We’re grateful to Precision Medicine Online for highlighting Alto Neuroscience’s mission to bring precision psychiatry to patients who need better options. By using EEG biomarkers, we aim to match the right treatment to the right patient — so people living with depression, schizophrenia, and other mental health conditions can find relief faster and more effectively. Thank you to the journalists and advocates who help share these stories of hope and progress. Together, we can change how psychiatric care is delivered. Read the full article here: https://lnkd.in/gghX7imu #MentalHealth #PrecisionMedicine #EEG #PatientCare #Community

This week, our CEO, Amit Etkin, will discuss Alto’s recent corporate updates during a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. Tune in here: https://lnkd.in/ewXjWAPH

Meet Kelsey Dock, MBA, MHSM, Senior Clinical Research Associate at Alto Neuroscience. Kelsey plays a key role in bridging scientific innovation with real human impact, helping to advance our mission to develop precision psychiatry treatments that are more effective, accessible, and personalized. Outside of Alto, Kelsey finds balance by staying active—whether through new fitness challenges or exploring new places. These pursuits keep her grounded and energized, fueling the passion she brings to her work every day. #MeetTheTeam

We’re heading to New York City! Our CEO, Amit Etkin, will discuss Alto’s recent corporate updates during upcoming investor conferences. Learn more: https://lnkd.in/eVuaKARY

Our CEO, Amit Etkin joined NYSE, to unpack how AI is reshaping biotech from discovery through the clinical trial lifecycle. Hear Amit’s perspective on the biotech sector’s growing adoption of #AI and #MachineLearning, and how Alto is redefining #PrecisionPsychiatry through data-driven innovation.